Serum inflammatory markers as predictors of therapeutic response in non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease: a retrospective cohort analysis
Authors:
Open Access
- 10 May 2025
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 25 (1) , 1-12
Abstract
The role of chronic inflammation in non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease (non-IPF f-ILD) remains unclear, with varied responses to anti-inflammatory or immunosuppressive therapy. A reliable predictor for guiding treatment response may enhance clinical decision-making and minimize adverse treatment effects. We hypothesized that elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) may be associated with improved treatment response. Our retrospective cohort study compared treatment response to anti-inflammatory therapy in patients with non-IPF f-ILD stratified by baseline CRP and ESR levels. Treatment response was defined as: (1) relative increase in percent predicted forced vital capacity (FVC%) ≥ 5% in 6 months or ≥ 10% in 12 months; or (2) no change or any increase in FVC% if FVC% decline was noted prior to treatment. Logistic regression was used to delineate outcome predictors with FVC% change over time assessed with linear mixed effects models. Of 832 non-IPF f-ILD patients screened, 167 received anti-inflammatory therapy and baseline inflammatory marker testing stratified into high vs. low-to-normal groups (104 vs. 63, respectively). Median age was 64 years, and 57% were diagnosed with a systemic autoimmune rheumatic disease (SARD). Treatment response was greater in those with elevated inflammatory markers (56% vs. 35%; OR 2.45 [1.243–4.828] P = 0.010) even after adjustment for a priori covariables. SARD diagnosis was associated with treatment response (OR 2.90 [1.45–5.81] P = 0.003), independent of inflammatory marker level. A positive FVC% slope was observed in treated patients with initially elevated inflammatory markers (P = 0.003). Patients with non-IPF f-ILD and elevated inflammatory markers appear to be more responsive to anti-inflammatory therapy with slower FVC decline over time. These findings suggest baseline serum ESR and CRP may be feasible and reliable predictors of treatment response in certain subgroups.Keywords
This publication has 20 references indexed in Scilit:
- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic DiseasesArthritis Care & Research, 2024
- Lung imaging patterns in connective tissue disease–associated interstitial lung disease impact prognosis and immunosuppression responseRheumatology, 2024
- Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohortRheumatology, 2023
- Interstitial pneumonia with autoimmune features and histologic usual interstitial pneumonia treated with anti-fibrotic versus immunosuppressive therapyRespiratory Investigation, 2023
- Successful treatment by mycophenolate mofetil of subacute progressive interstitial lung disease associated with systemic lupus erythematosusModern Rheumatology Case Reports, 2020
- Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialThe Lancet Respiratory Medicine, 2020
- Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity PneumonitisChest, 2017
- Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung diseaseRespiratory Medicine, 2016
- Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialThe Lancet Respiratory Medicine, 2016
- A long-term study of interstitial lung disease in systemic lupus erythematosusSeminars in Arthritis and Rheumatism, 1990